前苏联专利SU1662352A3 Strain of bacteria escherichia coli

专利PDF首页>>前苏联专利

专利附录

专利说明

权利要求

类似技术

同族专利

引用文献

法律状态

优先权

专利摘要:
Tissue plasminogen activator (t-PA) derivatives are produced in useful quantities using recombinant DNA techniques. Specific derivatives include amino acid deletion derivatives and amino acid substitution derivatives. A deletion derivative lacking the N-terminal first 68 amino acids is specifically exemplified having requisite t-PA characteristics. The invention disclosed thus enables the production of t-PA derivatives via recombinant means. Methods, expression vehicles and various host cells useful in the production of said t-PA derivatives are also disclosed.
公开号:SU1662352A3
申请号:SU833595638
申请日:1983-05-04
公开日:1991-07-07
发明作者:Ваннорман Геддель Давид；Джек Кор Вильям；Пенника Диане；Аллен Вехар Гордон
申请人:Генентек, Инк (Фирма)；
IPC主号:

专利说明:

The invention relates to a human plasminogen activator and a new bacterial strain transformed with the plasmid p: -pA1: gr12-producer of a tissue-type plasminogen activator.
EXAMPLE 1 Human melanoma cells are cultured in 100 ml of Eagle's medium supplemented with sodium bicarbonate (final concentration 0.12%), 2 mM glutamine and 10% fetal bovine serum heated by heating. The cells are washed once with phosphate buffer and 0.3 ml of serum and methionine free medium are added. 75 µCi (353) -methionine is added, incubated at 37 ° C for 3 hours, then the medium is removed and treated with either a specific 1 gG tissue plasminogen activator or 1 pre-immune serum for immunoassay. Immunoprecipitation products are subjected to electrophoresis in a 10% SDS-acrylamide gel. The gel plate is fixed, dried and subjected to fluorography.
From cells of meganoma extracted RNTS. The cells are centrifuged, resuspended in 10 mM NaCl, 10 mM Tris-HCl (pH 7.5), 1.5 mM MgCl2, lysed by the addition of NP-40 (final concentration 1%), and the cores are precipitated by centrifugation. The supernatant containing all of the RNA is purified by multiple extractions with phenol and chloroform. The salt concentration in the aqueous phase is adjusted to 0.2 M NaCl. RNA is precipitated by adding two volumes.
se
1HE
WITH
ate yu

CN
stir ethanol and chromatograph on oly ro-d T-cellulose. The yield of 10 g of cultured melanoma cells is 5-10 mg of total RNA and 50-200 µg of polyA mRNA.
PolyA mRNA (200 µg) is fractionated by electrophoresis through urea – agarose gel: 1.75% agarose, 0.025 M sodium citrate (pH 3.8) and
6 M urea for 7 hours at 25 mA and 4 ° C. The gel is cut with a blade. Individual thin layers in the form of slices are melted at 70 ° C and extracted twice with phenol and once with chloroform RNA precipitated with ethanol and subsequently tested by in vitro translation in a rabbit cell lysate reagent system, supplemented with canine pancreatic microsomes, in a weak way. Translation is performed using 25 µCi of (358) -methionine and 500 ng of RNA from each thin gel layer in 30 µl of medium containing 25 mM HEPES, 48.3 mM potassium chloride, 10 mM creatine phosphate, 19 amino acids 50 mM each 1.1 mM magnesium chloride, 16.6 mM EDTA, 0.16 mM dithiothreutol, 8.3 mM hemin, 16.6 mg / ml creatine kinase, 0.33 mM calcium chloride, 0.66 mM EDTA 23.3 MI sodium chloride. Incubation is carried out at 30 ° C for 90 minutes. Translation products or immunoprecipitated translation products are analyzed by electrophoresis on 10% polyacrylamide gels and sodium dodecyl sulfate. Plates of gels are fixed, dried, and subjected to fluorography.
„
The resulting translation products from each gel fraction are immuno-precipitated. One major band of the immunoprecipated polypeptide is observed, having a molecular weight of approximately 63,000 daltons.
5 µg of gel-graded mRNA is used to prepare a double chew cDNA using standard procedures. Fractionation of cDNA in size and 6% polyacrylamide gel. Electronically cDNAs are larger than 350 base pairs (125 ng). 30 ng of cDNA with deoxy (C) residues are transformed into 300 ng of plasmid pBR 322 with deoxy (C) residues in the PstI region. The mixture is then transformed into E. coli Ј12 strain 294 (ATCC-31446). Approximately 4,600 transformants are obtained.
Q
five
.
five
2 mg of a sample of tissue plasminogen activator sample is dialyzed against 0.01% Tween 80 overnight at room temperature. The lyophilized protein is then dissolved in 12 ml of 0.56 M Tris-HCl buffer (, 6), 8 M urea and 5 mM EDTAo. Disulfide bonds are reduced by adding O, 1 ml B-mercaptoethanol. This reaction is carried out in nitrogen for 2 hours at 45 ° C. The reduced disulfides are alkylated with carboxymethyl derivative by adding 1.0 ml of 1.4 M iodoacetic acid in 1N. NaOH, after 20 min, the reaction is stopped by dialysis against Tween 80 and lyophilized. The lyophilized carboxymethylated protein is again dissolved in 3 ml of 0.1 M sodium phosphate buffer (pH 7.5), trypsin (TRNC) is added in a ratio of 1:50 and kept at 37 ° C. The second addition of trypsin is carried out after 12 hours. After 24 hours, complete peptide cleavage is observed.
0.5 ml of the sample is applied to a high resolution Altex C-8 ultrasphere 5 μm column with two cycles. Set a gradual gradient of acetonitrile (from 1 to 5% in 5 minutes, from 5 to 35% in 10 minutes, 35-50% in 30 minutes). The eluent is controlled by two wavelengths (210 and 280 nm).
After determining the sequence of approximately 25 best possible peptide peaks, they are combined to obtain a preliminary model of the primary structure of the tissue plasminogen activator,. So, several possible probes are obtained.
Colonies are individually inoculated into the holes of the microtitre plates containing LB + 5 µg / ml tetracycline after adding DMSO to 7% and stored at -20 ° C. Two copies of the colony pool are grown on nitrocellulose filters and the DNA of each colony is fixed on the filter.
A 32P-labeled TC / / CA / / TA / t / TCCA synthetic oligomer probe was prepared. Filters containing 4600 transformants are prehybridized for 2 hours at room temperature in 50 mM sodium phosphate (pH 6.8), 5XSSC, 150 μg / ml ultrasonic salmon sperm DNA, 5x Denhardt solution, H) formamide, and then hybridized from 5k106 imp / min labeled probe. After incubation overnight
at room temperature, the filters are washed 3 times in 6xSSC, 0.1% SDS for 30 min, once in 2xSSC, and then exposed to x-ray film.
Plasmid DNA was isolated from all colonies showing a positive hybridization reaction. The sequences of the cDNA inserts of these clones are determined after subcloning the fragments in M13 vector MP 7. One cDNA insert in clone 25E10 has DNA encoding a tissue plasmogenogen activator. Clone 25E10 has 2304 base pairs in length and the longest structure encoding a protein of 508 amino acids (Molecular weight 56756) and contains 772 bp of the untranslated region „
50 µg of pP25E10 are cleaved with PstI restriction enzyme and a fragment of 376 bp is isolated. electrophoresis in 6% polyacrylamide gel. 3 µg of this fragment are digested with restriction enzyme
Ddel for 1 h at 37 ° C, extracted with phenol and chloroform and precipitated with ethanol. The resulting Ddel sticky ends are treated with 5 units of DNA polymerase I (Klenow fragment). After extraction with phenol and chloroform, the DNA is digested with 15 units of Narl restrictase for 2 h and subjected to electrophoresis on a 6% polyacrylamide gel. Approximately 0.5 μg of a 125 bp fragment is recovered. with a blunt end narl. This fragment encodes amino acids from 69 to 110 of the full-length mature tissue plasminogen activator protein.
30 µg of pP25E10 are cleaved with 30 units of Narl and 35 units of Bglll for 2 hours at 37 ° C and the reaction mixture is subjected to electrophoresis in
6% polyacrylamide gel. Approximately 6 µg of 1645 i.e., are isolated. Narl-Bglll fragment.
Ita RISRC paradise plasmid is a derivative of plasmid psR Cex 16, in which the Eco RI sites proximal to the trp promoter and distal to the SRC gene was removed by DNA polymerase I repair of po- inserted and self-complementary oligonucleotide AATTATGAATTCAT, synthesized by the phosphotriester method. 20 μg of this plasmid was digested with EroRI, extracted with phenol and chloroform and precipitated
50
five
0
five
0
five
0
nol. The plasmid is then cut with 100 units of Nuclease SI at 16 ° C for 30 minutes in 25 mM sodium acetate (pH 4.6), 1 mM ZnCl2 and 0.3 M NaCl to create a blunt end with the ATC sequence. After extraction with phenol and chloroform and precipitation with ethanol, the DNA is restricted with BamHI, electrophoresis is carried out in a 6% polyacrylamide gel and a large (4300 bp) fragment of the vector is recovered.
The expression plasmid was harvested with a compound of 0.2 μg of a vector, 0.06 μg of a fragment of 125 bp. with a blunt end Narl and 0.6 µg fragment 1645 p. Nar-Bglll with 10 units of T4 DNA ligases for 7 hours at room temperature and transformed into E.coli strain 294 (ATCC No. 31446).
Plasmid DNA from 26 colonies was isolated and digested with restriction enzymes Xbal and EcoRI. 12 of these plasmids contain fragments of 415 bp. Xbal-EcoRI and 472 p. EcoRI. DNA sequence analysis confirms that some of these plasmids have an ATS, the initial codon correctly located at the beginning of amino acid number 69 (series). One of these plasmids produces a tissue plasminogen activator.
3 µg of human lymphocyte DNA is completely cleaved with various endonucleases, electrophoresis is performed on 1.0% agarose gels and transferred to a nitrocellulose filter. Prepare P-labeled DNA as a probe from the insert 5 of the end of the cDNA clone pP25E10 (fragment 230 bp Hpall-RSAl) and hybridize with a nitrocellulose filter for 40 hours, then the filter is washed. The data obtained indicate the presence of a single gene of tissue plasminogen activator in the human genome.
Reconstruction of the complete coding sequence is possible using the normal Hhal restriction endonuclease region, divided into two partial clones pP17 and PA25E10. A 55 bp restriction fragment was isolated from the pP17 plasmid. Sau 3AI- Hhal, corresponding to amino acids 5-23. A 263 bp fragment was isolated from the pP25E10 plasmid. Hhal-Narl (encoding amino acids 24-110). Two synthetic deoxy oligonucleotides are constructed that reconstruct codons.
l amino acids 1-4, include the codonization of the translation of the ATS and create an EroRI sticky ending, These three fragments are then linked together to form 338 bp. a fragment that coats amino acids 1-110. This fragment and fragment 1645 p. Narl-Bglll from pP25E10 is then linked by EcoRI and Bglll to the pLelPAtr p 103 plasmid to produce the pt-PAtrp12 expression plasmid.
E. coli K12 strain W3110 (ATCC No. 27325) containing plasmid pt-PAtrp12 ,, is grown, and extracts are prepared for samples for fibrinolytic activity. The amount of plasmin formed is determined by measuring the degree of fibrin cleavage on an agarose plate containing plasminogen and fibrin. Plasmin gives a clear lysis zone on the fibrin plate and the area of this zone correlates with the amount of tissue plasminogen activator in the sample. When testing extracts from pt-PA trp12 clones for the activity of a tissue plasminogen activator, samples with a fibrin plate are used to form a clear zone of lysis. This fibrinolytic activity is inhibited with anti-t-up IgG, but is not pre-immunized with IgG or IgG anti-Eurokinase. The extract obtained from cells containing the leucocyto-interferon plasmid pLelFtrp 103 as a control does not show activity. Approximately 20 units of extracted activity per 10 cells are obtained (for a purified t-AL 90000 units of Plow 1 mg) „
The resulting bacterial strain E.coli ATC C31446 is characterized by the following properties.
It has the endA, Thi, hsr, hsm геп hepotype.
It grows in LB medium (10 g bactotrip- 5 g baktolodzhevogo extract and 10 g sodium chloride per liter of medium).
For storage in 3 ml of LB overnight culture, 2 ml of 50% glycerol is added, stirred and frozen in sterilized bottles at -20 ° C. PRI mme R 2. A colony of E. coli containing the plasmid puRIPA0 is grown in 5 ml of LB growth medium containing 20 μg / ml of ampicillin overnight at 37 ° C. An aliquot of this culture is diluted 1: 100 in 300 ml of M9 medium containing 20 µg / ml ampicillin, and
five
0
five
0
five
0
five
0
five
grown at 37 ° C for 4 h to a density of OE550 0.419. Tryptophan analog of indole acrylic acid is added to a concentration of 30 µg / ml. Incubate cells for 90 minutes until the density of OB sso - 0.628. The cells are centrifuged and resuspended in 0.8 ml of 0.01 M Tris buffer (pH 8.0) containing 0.01 M EDTA. The resulting suspension is vigorously stirred for 18 hours at room temperature. Samples were centrifuged and the supernatant layer checked for activity of the tissue plasminogen activator.
Tables 1 and 2 show the results obtained when plasminogen is activated with the appropriate E.coli extracts.
The generated activity depends on the presence of plasminogen (Table 1). This activity is not caused by rabbit pre-immune serum, but it is clearly inhibited by antiserum, which was obtained against a tissue plasminogen activator derived from purified melanoma cells (Tables 1 and 2). This indicates that E. coli extracts give plasminogen activation activity, which is inhibited by antibodies against tissue plasminogen activator.
Example 3: Production of t-up using a DHFR protein with low binding affinity for MTT.
A sequence encoding a tissue plasminogen activator (mTAP) is inserted into a plasmid containing mutant DHFR with low binding affinity for MTT. For this, three fragments of partially overlapping t-AP shtazmid, pPA25E10 and pPA17, and PURIPA (above) are prepared as follows.
The pP17 plasmid was digested with the Ddel restriction enzyme, treated with the Klenow fragment of the DNA polymerase I, cleaved with the restriction enzyme PstI, a fragment of approximately 200 bp in size containing the T-AP terminal sequence was isolated. A second t-AP fragment was obtained by cleavage of puRIPA with PstI and Narl, and a fragment of 310 bp was isolated. The third t-AP fragment is obtained by pPA25E10 cleavage with Narl and Bglll and a 1645 bp fragment is isolated, which also contains most of the c-AP coding region and some
number of non-translated sequences.
The plasmid pE342, which expresses the NVU surface antigen, is digested with Hindlll, Hindlll ends 4 are converted into EcoRI ends by adding a converter (AGCTGATTC). This DNA is cut with PvuII and RI bindings are added. Subsequent cleavage of EcoRI leads to the selection of a fragment of 348 p. O it is cloned into pBR322. An expression plasmid of pH expression 348-E was constructed by cloning a 1986 bp fragment. the resulting HBV hydrolysis with EcoRI and Bglll, then linearized with pRI-Bgl and EcoRI and introducing the 348 bp fragment, which is the original SV 40 region, and the EcoRI portion of the pRI-Bgl is modified with pЕ342 by partial hydrolysis with EcoRI, filled in with cleaved the region using the Klenow fragment of DNA polymerase I and then binding part of the plasmid .. The resulting plasmid pE342URI is hydrolyzed with EcoRI, treated with the Klenow fragment of DNA polymerase I and digested with BamHI. A 3500 bp fragment is obtained by acrylamide gel electrophoresis, extracted with phenol and chloroform, and precipitated with ethanol.
Thus obtained vector p342E 3500 p. bind to t-AP fragments of about 2,160 bp in size using standard techniques. A plasmid containing the three t-AP encoding fragments in the desired orientation is isolated, the pE342-t-AP is characterized and cut out. This plasmid is hydrolyzed with SacII and treated with bacterial alkaline phosphatase (BRL). To provide the DHFR sequence, a fragment of approximately 1700 bp was isolated by hydrolyzing SacII pEHeR (pEHeR is a plasmid expressing the mutant DHFR). This fragment is inserted into the pE342-t-AP plasmid to create the pEdPAER 400 plasmid, which is similar to the pEHER except that the HBS Ag coding region is replaced by cDNA sequences from t-AP.
PETRAE 400 XpETPER was transfected into dhfr-CHO DIH B11 cells and DGFR + CHO K1 (ATCC CCL 61) cells. Transformed dhfr cells are selected by growing on medium devoid of glycine, hypoxanthine and ty.
0
0
five ,.
five
0
five
0
five
midina. Transformed DHFR cells were selected by growing in 100 mM MTT. Colonies that arise on the appropriate selection medium are isolated using cloning cycles and propagated on the same medium to several generations.
To amplify colony cells
g
grown in medium containing 5 10 10G, 2.5 10s, 5-U5 and 106 nM MTT.
The DNA of the amplified colonies is isolated as follows. The monolayers are washed in 150 mm plates with 50 ml of sterile pBS and lysed by adding 5 ml of 0.1% SDS, 0.4 M CaClA, 0.1 M EDTA (pH 8), after 5-10 minutes, extracted with phenol, then with chloroform 1 mom and precipitated with ethanol. The DNA pellet was suspended in 1 ml (150 mm plate) of 10 mM Tris / HCl, pK 8.1 mM EDTA (TE), GNCase was added to 0.1 mg / ml and incubated for 30 minutes at 37 ° C.
Then, SDS was added to O, 1% s sample to 0.5 mg / ml, incubated for 3-16 hours at 37 ° C, extracted with phenol, chloroform and precipitated with ethanol. The precipitated DNA is suspended in 0.5 ml of water, hydrolysis with cosiness with restriction enzymes and subjected to electrophoresis on a 1% agarose gel, then the gel is removed and stained. After imaging in ultraviolet light, the DNA is transferred to nitrocellulose filters, and the filters are hybridized with a SacII-labeled DNA fragment of 1700 bp. plasmids pEHER or Bglll DNA fragment size 1970 p. o, plasmids PETPER.
The plasmid pETPFR is used to transfect cells lacking DHFR. Test 21 colonies that are grown on selective medium (-GTT), by detection on the formation of plasmin. Four clones with the same or comparable t-up secretion are detected.
The indicated subclones in the amount of 2-10 cells are placed on plates of 100 mm in 50 nM MTT, selected again, two clones are selected for further study and are named
1-15 and 18V-9.
Subclones 1-15 and 18B-9 after curing for about 1-2 months. test, For this, serially dilute purified t-AP and purified iodine-labeled t-AP, originating from melanoma cells, to a concentration of 12.5 to 400 mg / ml in buffer, contain phosphate buffered saline (pH 7.3) , 0.5% bovine albumin serum, 0.01% Tween-80 and 0.02% NaNq. Samples with appropriate dilutions of the medium are added to radioactively labeled proteins, and incubated overnight at room temperature in the presence of IgG of the anti-t-AP fraction of rabbit antiserum. The antigen – antibody complex is precipitated by absorbing kea-anti-rabbit IgG immunobunic (Vio Rad) for 2 hours at room temperature. The pellets are washed and the radioactivity, precipitation, is measured. Concentrations are determined by comparison with an internal standard.

权利要求:
Claims (1)
[1]
Amplified culture produces up to 50 pg per cell on day 1, t-up. Invention Formula
The strain of bacteria Escherichia coli ATSS 31446 (pt-pA) trp12 - producing plasminogen activator tissue type.
Table 1
Plasminogen activation extracts from E.coli cultures containing P & RIPA
Continuation of table 1
The percentage of activity is calculated by subtracting the blank experiment (0.043) from the obtained values and dividing by the obtained value of the extract.
Table 2
Plasminogen activation of EoColi extracts of pt-PAtrp12 cultures
thirty
Extract
0.657
(100)
Extract (without plasminogen)
0.043 (0)
Extract plus pre-immune serum
Extract plus anti-t-up antibodies
0.665
0.059
101

类似技术:

公开号 | 公开日 | 专利标题

SU1662352A3|1991-07-07|Strain of bacteria escherichia coli - a producer of plasminogen activator of tissue type

KR970002915B1|1997-03-12|Novel proteins with factor vñ� activity, process for their preparation using genetically-engineered cells

RU2009198C1|1994-03-15|Nucleic acid fragment encoding human proapolipoprotein a-1

US4994559A|1991-02-19|Human basic fibroblast growth factor

JP2687995B2|1997-12-08|DNA sequence, recombinant DNA molecule and method for producing human fibroblast interferon-like polypeptide

US4912038A|1990-03-27|Recombinant DNA sequence encoding alveolar surfactant protein

JPH07106144B2|1995-11-15|Human immune interferon

CS248705B2|1987-02-12|Production method of the activator of the human tissue plasminogen

JP3450844B2|2003-09-29|Factor XIIIa and method for producing the same

JPH09135691A|1997-05-27|Preparation of pregrowth and growth hormone of cattle

US5026839A|1991-06-25|DNA encoding a basic fibroblast growth factor

Hla et al.1986|Isolation of the cDNA for human prostaglandin H synthase

US4933280A|1990-06-12|Recombinant DNA sequence encoding Alveolar Surfactant Protein

EP0491878B1|1997-02-19|Compositions for the inhibition of protein hormone formation and uses thereof

JP2002526073A|2002-08-20|A coding sequence for a novel human growth differentiation factor, a polypeptide encoded by the DNA sequence thereof, and a method for producing them.

US5298489A|1994-03-29|DNA sequences recombinant DNA molecules and processes for producing lipocortins III, IV, V and VI

WO1986006100A1|1986-10-23|Human anti-inflammatory phospholipase inhibitor protein

US5646254A|1997-07-08|Antibodies for human phospholipase inhibitory protein |

EP0307513A2|1989-03-22|Pulmonary hydrophobic surfactant-associated proteins

PT89026B|1993-02-26|METHOD FOR PREPARING A NEUTROPHIL ACTIVATION FACTOR

JPH0787789B2|1995-09-27|DNA molecule encoding lipocortin and transformed host

EP0226181B1|1994-06-15|Human placenta angiogenic factor capable of stimulating capillary endothelial cell protease synthesis, DNA synthesis and migration

IE67564B1|1996-04-17|Monoclonal antibodies against interferon-induced human protein in pure form and test kits containing these antibodies

WO2004052927A1|2004-06-24|A baldness related gene and the polypeptide encoded thereby, and uses thereof

DK172400B1|1998-05-18|Process for preparing purified minactivin, a minactivin- encoding DNA molecule, a recombinant DNA molecule, a fused gene, a host, a reagent for locating and defining the limits of tumours in histological samples, and the use of recombinaint DNA molecule and the minactivin and peptides thereof

同族专利:

公开号 | 公开日

GT198302091A|1984-10-25|

JPS5942321A|1984-03-08|

KR840004781A|1984-10-24|

ZA833174B|1984-08-29|

JPS6291187A|1987-04-25|

HU200615B|1990-07-28|

MX197183A|1994-02-28|

JPH0134596B2|1989-07-20|

JPS6216931B2|1987-04-15|

US5763253A|1998-06-09|

引用文献:

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

IL43343A|1972-10-24|1976-03-31|Lilly Co Eli|Production of plasminogen activator|

US3904480A|1972-10-24|1975-09-09|Lilly Co Eli|Enhanced production of plasminogen activator|

US3998947A|1973-11-30|1976-12-21|Pierre Fabre S.A.|Process for obtaining a plasminogen activator|

CA1154671A|1979-07-27|1983-10-04|Lucien D. D'hinterland|Separation of a tissular activator ofplasminogen|

FR2252842B1|1973-12-03|1977-11-04|Fabre Sa Pierre|

FR2310133B2|1975-05-05|1978-12-01|Fabre Sa Pierre|

US4245051A|1978-03-30|1981-01-13|Rockefeller University|Human serum plasminogen activator|

US4190708A|1978-05-24|1980-02-26|Monsanto Company|Production of urokinase|

CH643297A5|1978-06-30|1984-05-30|Alpha Patent Ltd|Method for preparation of pure urokinase.|

DE3015699C2|1979-04-26|1982-07-15|Asahi Kasei Kogyo K.K., Osaka|Manufacture of a plasminogen activator|

US4370417A|1980-04-03|1983-01-25|Abbott Laboratories|Recombinant deoxyribonucleic acid which codes for plasminogen activator|

NL8003402A|1980-06-11|1982-01-04|Leuven Res & Dev Vzw|NEW PLASMINOGEN ACTIVATOR AND PHARMACEUTICAL PREPARATION WITH THROMBOLYTIC ACTION.|

JPH0446941B2|1980-12-25|1992-07-31|Idemitsu Kosan Co|

US5185259A|1982-05-05|1993-02-09|Genentech, Inc.|Truncated human tissue plasminogen activator|

US4853330A|1983-04-07|1989-08-01|Genentech, Inc.|Human tissue plasminogen activator|

US4766075A|1982-07-14|1988-08-23|Genentech, Inc.|Human tissue plasminogen activator|

JPH0357749B2|1982-08-02|1991-09-03|Asahi Kasei Kogyo Kk|

US5011795A|1983-01-19|1991-04-30|Genentech, Inc.|Human tPA production using vectors coding for DHFR protein|

EP0174835A1|1984-09-11|1986-03-19|The Upjohn Company|Human tissue plasminogen activator and recombinant DNA compounds|

FI85334C|1985-05-28|1992-04-10|Wellcome Found|Process for Preparation of an Aqueous Tissue Plasminogenic Tivator Containing Concentrated Parent Solution|

US5094953A|1988-03-21|1992-03-10|Genentech, Inc.|Human tissue plasminogen activator variants|IL68561A|1982-05-05|1991-01-31|Genentech Inc|Preparation of polypeptide with human tissue plasminogen activator function,processes for making it,and dna and transformed cell intermediates thereof|

PT88133B|1987-07-28|1995-03-01|Gist Brocades Nv|PROCESS FOR THE PREPARATION OF POLIPEPTIDEOS BY EXPRESSION IN KLUYVEROMYCES|

AU554862B2|1982-12-14|1986-09-04|Implico B.V.|Plasminogen activator isolated by affinity chromatography|

JP2648301B2|1983-12-27|1997-08-27|ジエネテイツクス・インスチチユ−ト・インコ−ポレ−テツド|Vector containing auxiliary DNA for transformation of eukaryotic cells|

JPH0521551B2|1984-01-30|1993-03-24|Asahi Kasei Kogyo Kk|

EP0178105B1|1984-10-01|1997-04-02|Genzyme Corporation|Recombinant DNA techniques and the products thereof|

EP0199801B1|1984-10-29|1993-08-25|MICROGENICS CORPORATION |Methods for protein binding enzyme complementation assays|

DD258026A5|1985-04-22|1988-07-06|Genentech Inc|Process for the preparation of human tissue plasminogen activator mutants|

GB8513358D0|1985-05-28|1985-07-03|Wellcome Found|Formulation|

AU593264B2|1985-07-10|1990-02-08|Kanegafuchi Kagaku Kogyo Kabushiki Kaisha|Chromosomal DNA sequence, expression vector for human tissue plasminogen activating factor, cultured cells transfected with same and method of producing said activating factor|

US4916071A|1985-08-14|1990-04-10|American Home Products Corporation|Poly-kringle plasminogen activator|

NL8503097A|1985-11-11|1987-06-01|Leuven Res & Dev Vzw|MEDICINAL PRODUCT WITH THROMBOLYTIC ACTION.|

DE3689620T2|1985-11-13|1994-06-16|Univ Hospital Boston|DNA MODIFIED BY CYS CODON.|

GB8528321D0|1985-11-18|1985-12-24|Ciba Geigy Ag|Modified fibrinolytic agents|

JP2837348B2|1985-11-27|1998-12-16|三井化学株式会社|Method for producing human tissue plasminogen activator derived from human normal cells|

DK623186A|1985-12-23|1987-08-26|Chiron Corp|POLYPEPTIDE WITH TISSUE PLASMINOGEN ACTIVATOR EFFECT|

IE81073B1|1986-03-18|2000-01-12|Genentech Inc|Modified human tissue-type plasminogen activator and its preparation|

JPH01500322A|1986-03-28|1989-02-09|

JPH0379000B2|1986-05-19|1991-12-17|Snow Brand Milk Prod Co Ltd|

JPS63196268A|1987-02-10|1988-08-15|Kanegafuchi Chem Ind Co Ltd|Transformant cell capable of being subjected to passage multiplication in serum-free medium, breeding thereof and production of protein by said cell|

AT120491T|1987-06-24|1995-04-15|Genentech Inc|BALANCED, CONSTITUTIVE, INDUCIBLE TRANSCRIPTION SYSTEM.|

JP2576200B2|1988-03-09|1997-01-29|味の素株式会社|Method for producing bioactive protein|

DE3923339A1|1989-05-31|1990-12-06|Boehringer Mannheim Gmbh|FABRIC PLASMINOGEN ACTIVATOR DERIVATIVE|

GB9022545D0|1990-10-17|1990-11-28|Wellcome Found|Culture medium|

法律状态:

优先权:

申请号 | 申请日 | 专利标题

US37486082A| true| 1982-05-05|1982-05-05|

[返回顶部]